Ethris Reports First Patient Dosing in P-IIa Trial of ETH47 for Asthma

Shots:Ethris has dosed the first pts in a P-IIa trial of ETH47 for asthma symptom reduction after rhinovirus challenge, building on P-I trial data, which showed strong respiratory tract activity, local IFNλ induction, antiviral gene activation, & no systemic exposureThe P-IIa trial will evaluate ETH47 vs PBO in ~50 adults with asthma who…

ByRidhi RastogiAugust 5, 2025

NEWS

Ethris Partners with Lonza to Develop Intranasal Spray-Dried mRNA Vaccines Against Respiratory Diseases

Shots:Ethris has entered into a collaboration agreement with Lonza to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates designed for mucosal delivery in pts with respiratory diseasesAs per the deal, Lonza will support Ethris’ vaccine candidates, which are based on Ethris’ stabilized non-immunogenic mRNA (SNIM RNA) & stabilized lipid nanoparticles (SNaP LNP)…

ByRidhi RastogiApril 7, 2025

TOP 20

Top COVID-19 Deals (Part I): Biopharma Drug Development

The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies- as well as government agencies- to partner at an unprecedented speed to develop vaccines- treatments- and testsThis article covers last four months of deal data provided by Chris Dokomajilar of DealForma.This first part is…

ByPrince GiriApril 17, 2020

Ethris Reports First Patient Dosing in P-IIa Trial of ETH47 for Asthma

Ethris Partners with Lonza to Develop Intranasal Spray-Dried mRNA Vaccines Against Respiratory Diseases

Top COVID-19 Deals (Part I): Biopharma Drug Development

Contact US

OUR INFORMATION

FOLLOW US